Imbio PHA (4.0.0) vs Fetal EchoScan
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Imbio PHA analyzes CT pulmonary angiogram scans in adults to assess right ventricular dilation for conditions like pulmonary embolism and hypertension. In contrast, Fetal EchoScan utilizes AI-powered ultrasound for prenatal detection of congenital heart defects in fetuses. While both are FDA-cleared cardiac imaging AI tools, their distinct imaging modalities, patient populations, and specific clinical applications make them suitable for entirely different diagnostic pathways.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Imbio PHA (4.0.0) is designed for adult patients, analyzing CT pulmonary angiogram (CTPA) scans to measure cardiac structures for assessing right ventricular dilation, aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension. Fetal EchoScan, conversely, is intended for pregnant women aged 18 or older undergoing second-trimester anatomic ultrasound exams, assisting clinicians in the prenatal detection of congenital heart defects (CHDs) in developing fetuses.
Imbio PHA (4.0.0) processes CT pulmonary angiogram (CTPA) scans. Fetal EchoScan integrates with existing ultrasound workflows and is specifically designed for prenatal ultrasound examinations of the fetal heart.
Imbio PHA (4.0.0) is HIPAA compliant, with third-party certification by Compliancy Group, and implies a Business Associate Agreement (BAA) is in place. For Fetal EchoScan, HIPAA compliance and the availability of a BAA are stated as 'likely, contact vendor'.
Imbio PHA (4.0.0) automatically measures right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios. Fetal EchoScan provides AI-driven support for prenatal ultrasound examinations, including automated detection of congenital heart defects, real-time guidance, and feedback to ensure exam completeness and reduce errors.
These tools address distinct clinical needs and are not interchangeable. Imbio PHA (4.0.0) focuses on assessing right ventricular dilation from CTPA scans in adults for conditions like pulmonary embolism and hypertension, while Fetal EchoScan specializes in the prenatal detection of congenital heart defects in fetuses using ultrasound.